Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GPR183 | P32249 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427542 | 0.86 | ALDH1A1 (0.58) | ALDH1A1KDM4EPOLBTNIKMMP1 | |
| SCHEMBL24266769 | 0.83 | THRB (0.47) | KCNH2 | |
| SCHEMBL17108495 | 0.83 | LMNA (0.59) | ALDH1A1KDM4EPOLBOPRM1OPRK1 | |
| SCHEMBL3859171 | 0.83 | SIGMAR1 (0.49) | POLBOPRM1OPRK1OPRL1LTA4H | |
| SCHEMBL26656812 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KDM4EPOLBTNIKMMP1 | |
| SCHEMBL27042925 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KDM4EPOLBTNIKHPGD | |
| SCHEMBL653329 | 0.82 | OPRL1 (0.67) | ALDH1A1POLBOPRM1OPRK1OPRL1 | |
| SCHEMBL1427267 | 0.81 | TNIK (0.47) | ALDH1A1KDM4EPOLBTNIKSMN1; SMN2 | |
| SCHEMBL1427587 | 0.80 | ALDH1A1 (0.51) | ALDH1A1KDM4EPOLBTNIKMMP1 | |
| SCHEMBL4591704 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KDM4EPOLBTNIKMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022094-A1 | Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4558480-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-120019042-A | Compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2024019957-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024019957-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-101296906-A | (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | ALDH1A1 3960/4885KDM4E 1313/4885POLB 3623/4885 |
| US-20260022094-A1 | Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, CLN6, S1PR1 | ALDH1A1 1518/4885KDM4E 2571/4885POLB 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.